SANGAMO THERAPEUTICS, INC. (SGMOQ) Return on equity 2016–2024
SANGAMO THERAPEUTICS, INC. (SGMOQ) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-430.1%FY2024 · since FY2016: -52.6% → -430.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -430.1% | -119.1 pp |
| FY2023 | -311.1% | -245.9 pp |
| FY2022 | -65.2% | -17.7 pp |
| FY2021 | -47.5% | -23.2 pp |
| FY2020 | -24.3% | -2.3 pp |
| FY2019 | -22.0% | -3.4 pp |
| FY2018 | -18.6% | +10.4 pp |
| FY2017 | -29.0% | +23.6 pp |
| FY2016 | -52.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SGMOQ financial trends
SGMOQ RevenueSGMOQ Net incomeSGMOQ Net marginSGMOQ Gross profitSGMOQ Gross marginSGMOQ Operating incomeSGMOQ Operating marginSGMOQ Operating cash flowSGMOQ Free cash flowSGMOQ Capital expendituresSGMOQ Stock buybacksSGMOQ Dividends paidSGMOQ Total assetsSGMOQ Total liabilitiesSGMOQ Shareholders’ equitySGMOQ overview →